Antiplatelet Modulation Strategies After PCI in Patients Without an Indication for Oral Anticoagulation
Year: 2026
Type: article
Abstract: Dual antiplatelet therapy (DAPT) is central to the prevention of thrombotic complications after percutaneous coronary intervention (PCI). However, its optimal composition and duration are not uniform across all settings. Both ischemic and bleeding risks peak early after PCI, although their relative balance changes dynamically over time. This has shifted contemporary practice from standard DAPT regimens toward modulation of antiplatelet therapy by means of de-escalating and escalating the intensity of platelet inhibition tailored to clinical risk, procedural complexity, medication adherence, and time from PCI. In this narrative review, we examine randomized evidence on de-escalation and escalation antiplatelet strategies in patients undergoing PCI. De-escalation may be achieved through antiplatelet discontinuation, dose reduction, or switching. Among these approaches, aspirin withdrawal followed by P2Y12 inhibitor monotherapy with ticagrelor has the strongest evidence, particularly after an initial event-free period. Guided and unguided switching strategies may further refine treatment in selected patients. Conversely, escalation through increased doses, prolonged or additional antiplatelet therapy, or switching to more potent P2Y12 inhibition may be considered in patients in whom residual ischemic risk outweighs bleeding risk. Contemporary European and American guidelines increasingly reflect this risk-adapted approach. In conclusion, antiplatelet therapy following PCI should not be considered a “one size fits all” approach, but rather a strategy that needs to be tailored according to the patient’s risk profile that may need adjustments during the course of the patient’s follow-up.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15228860
Authors: Felice Gragnano, Vincenzo De Sio, Antonio Capolongo, Giuseppe Verde, Giovanni Pio Iannotti, Angelo Romano, Elio Mattia Migliaccio, Michelangelo Luciani, Gabriele Cappiello, Elisabetta Moscarella, Simona Sperlongano, Vincenzo Acerbo, Arturo Cesaro, Dobromir Dobrev, Antonio Landi, Diana A. Gorog, Dominick J. Angiolillo, Marco Valgimigli, Paolo Calabrò
Institutions: University of Campania "Luigi Vanvitelli", Baylor College of Medicine, Montreal Heart Institute, University of Duisburg-Essen, Université de Montréal, Ente Ospedaliero Cantonale, Istituto Cardiocentro Ticino, Università della Svizzera italiana, University of Hertfordshire, King's College London, Guy's and St Thomas' NHS Foundation Trust, Royal Brompton Hospital, East and North Hertfordshire NHS Trust, Imperial College London, University of Florida, University of Florida Health Science Center, University of Bern, University Hospital of Bern
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7225905070
